Product News Archives | Page 3 of 15 | Aurobindo Pharma USA

Currently Browsing

All Product News

April 14, 2025


Aurobindo Receives FDA Approval for Allopurinol Tablets USP, 100 mg and 300 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Allopurinol Tablets USP, 100 mg and 300 mg. Aurobindo Pharma’s Allopurinol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Zyloprim Tablets manufactured by Casper Pharma LLC. Allopurinol Tablets […]

April 10, 2025


Aurobindo Receives FDA Approval for Rivaroxaban Tablets USP, 2.5 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Rivaroxaban Tablets USP, 2.5 mg. Aurobindo Pharma’s Rivaroxaban Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Xarelto Tablets manufactured by Janssen Pharmaceuticals, Inc. (Janssen). Rivaroxaban Tablets are indicated: […]

April 04, 2025


Aurobindo Receives FDA Approval for Dapsone Gel, 5%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dapsone Gel, 5%. Aurobindo Pharma’s Dapsone Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Aczone Gel manufactured by AbbVie Inc. Dapsone Gel are indicated for the: Topical treatment […]

March 31, 2025


Aurobindo Receives FDA Approval for Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg. Aurobindo Pharma’s Pantoprazole Sodium for Delayed-Release Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Protonix for Delayed-Release Oral Suspension […]

March 21, 2025


Aurobindo Receives FDA Approval for Nystatin Cream USP, 100,000 units per gram

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nystatin Cream USP, 100,000 units per gram. Aurobindo Pharma’s Nystatin Cream, are an AB-rated generic equivalent to the reference listed drug (RLD), Nystatin Cream manufactured by Taro Pharmaceuticals Inc., Nystatin Cream are […]

February 27, 2025


Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.025%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tretinoin Gel USP, 0.025%. Aurobindo Pharma’s Tretinoin Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Retin-A® Gel manufactured by Bausch Health US, LLC. Tretinoin Gel are indicated for: […]

January 13, 2025


Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.01%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tretinoin Gel USP, 0.01%. Aurobindo Pharma’s Tretinoin Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Retin-A® Gel manufactured by Bausch Health US, LLC. Tretinoin Gel are indicated for: […]

January 02, 2025


Aurobindo Receives FDA Approval for Glycopyrrolate Oral Solution, 1 mg/5 mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Glycopyrrolate Oral Solution, 1 mg/5 mL. Aurobindo Pharma’s Glycopyrrolate Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Cuvposa® Oral Solution manufactured by Merz Pharmaceuticals, LLC. Glycopyrrolate Oral […]

December 26, 2024


Aurobindo Receives FDA Approval for Deutetrabenazine Tablets, 6 mg, 9 mg, and 12 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Deutetrabenazine Tablets, 6 mg, 9 mg, and 12 mg. Aurobindo Pharma’s Deutetrabenazine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Austedo® Tablets manufactured by Teva Branded Pharmaceuticals Products […]

December 12, 2024


Aurobindo Receives FDA Approval for Clozapine Orally Disintegrating Tablets, 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clozapine Orally Disintegrating Tablets, 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg. Aurobindo Pharma’s Clozapine Orally Disintegrating Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), […]

November 12, 2024


Aurobindo Receives FDA Approval for Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg. Aurobindo Pharma’s Cimetidine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Tagamet® Tablets manufactured by Glaxosmithkline […]

October 15, 2024


Aurobindo Receives FDA Approval for Metronidazole Gel USP, 1%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Metronidazole Gel USP, 1%. Aurobindo Pharma’s Metronidazole Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), METROGEL® manufactured by Galderma Laboratories, L.P. Metronidazole Gel are indicated for: The topical […]